Developer docs
API playgroundTry for free, no card

Search company profiles

AV8 Ventures

Full company profile

uuid0000g5z

Namestring
AV8 Ventures
Legal namestring
AV8 Ventures
Websiteurl
av8.vc
Company typeenum
Private
Founded yearint
2021
Descriptiontext

AV8 Ventures is an early-stage venture capital firm headquartered in Palo Alto, California, that invests Seed and Series A capital into startups across four core sectors: healthcare, enterprise software, financial technology and services, and deep tech. Founded in 2018, the firm positions itself as a "full lifecycle investor" that commits early and partners with founders for the long term, providing capital alongside operational expertise and network access. Its portfolio spans approximately 16 named companies, including women's telehealth provider Alpha Medical, cancer-detection startup Delfi Diagnostics, device security firm Eclypsium, mobile observability tool Embrace.io, biotech platform Think Bioscience, healthcare workforce intelligence platform Axuall, Medicare Advantage carrier Clever Care Health Plan, community health value-based-care operator Yuvo Health, microfluidic immunotherapy platform Shennon Bio, AI-based security automation tool Cerby, manufactured-home insurer Covertree, digital SMB insurance agency Glow, cyber insurance carrier Measured Analytics and Insurance, data intelligence platform DataGalaxy, workplace safety wearable Soter Analytics, and financial crime risk scoring firm Elucidate.

The firm's core offering is direct minority equity investment rather than a software product or technology platform. Its differentiation rests on a small core investment team — Managing Director and founder George Ugras, healthcare-focused partner Ruchita Sinha, partner Brett Battles, operating partner Serpil Kuyucak Schiebel, and venture partner Shawn Kung — supplemented by an external bench of approximately ten venture advisors drawn from companies including Asana, Google, UiPath, Square, LinkedIn, Fifth Third Bank, Zest AI, Stanford, and Nvidia. AV8 markets itself through a content-driven approach, publishing sector white papers on enterprise automation, healthcare innovation, and mobility/autonomy, alongside a blog featuring founder interviews and insurtech commentary.

AV8 Ventures generates revenue through the conventional venture capital model of management fees and carried interest on its fund vehicles. Fund II, a $180 million vehicle, was launched in September 2021 with capital commitment from Allianz, one of the world's largest integrated financial services providers. The Allianz relationship functions simultaneously as an anchor LP, a source of patient capital, and a strategic differentiator that grants AV8 proximity to insurance industry expertise and distribution. The firm is privately held, has no public revenue disclosures, and operates from a single Palo Alto office with a core team of five members.

Short descriptiontext

AV8 Ventures is an early-stage venture capital firm based in Palo Alto that invests Seed and Series A capital in healthcare, enterprise, financial services, and deep tech startups. The firm manages a $180 million fund backed by Allianz.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, early stage funding, seed stage investments, healthcare venture capital, enterprise software investing
Industry2 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAI
Micro-VC & Angel Funds
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeManaged Services
Description

VC fund management generating returns through carried interest and management fees from Fund II, a $180M fund backed by Allianz.

av8.vc
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AV8 Ventures is an early-stage venture capital firm that deploys Seed and Series A capital into startups operating in healthcare, enterprise software, financial technology and services, and deep tech. The firm backs founders with equity capital, operational guidance, and access to a venture advisor network, committing early and partnering for the long term. Its capital is sourced primarily through managed funds (including AV8 Fund II, a $180 million vehicle backed by Allianz).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Backed by Allianz, one of the leading integrated financial services providers worldwide
Product overview1 text field

AV8 Ventures is a venture capital firm structured as a single unified investment platform. The firm backs early-stage start-ups focused on four key sectors: Healthcare, Enterprise, Financial Services, and Deep Tech. They typically invest at the Seed or Series A stage and commit early, partnering for the long term. The firm is backed by Allianz and manages multiple funds (including AV8 Fund II, a $180M fund). The investment offering includes capital deployment, operational expertise, network access, and venture advisor support to help founders build their companies.

Product and service1 record
1AV8 Ventures Investment Services
CategoryVenture Capital Fund Management
Description

Early-stage venture capital investment services providing Seed and Series A equity financing to founders building category-defining companies in healthcare, enterprise software, financial technology and services, and deep tech, with operational support and venture advisor network access.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Costanoa Ventures
TypeDirect peer
Description

Early-stage venture firm focused on enterprise software and fintech, with offices in Palo Alto. Directly comparable to AV8 for deal flow in B2B software and similar Seed/Series A stage investing approach.

TypeDirect peer
Description

Palo Alto-based early-stage VC investing Seed/Series A across consumer, enterprise, and healthcare. Comparable stage, geography, and operator-friendly model to AV8's investment approach.

TypeDirect peer
Description

Early-stage venture firm investing Seed/Series A in enterprise, consumer, and healthcare. Directly comparable investment stage and thematic breadth to AV8's portfolio construction.

TypeDirect peer
Description

Early-stage VC investing across consumer, enterprise, fintech, and healthcare with an operator-driven platform model. Comparable to AV8 in stage, sector focus, and emphasis on operational support.

TypeDirect peer
Description

Seed-stage venture firm with focus on enterprise, mobile, and healthcare. Directly comparable to AV8 for early-stage deal flow and similar check sizes at the Seed stage.

6Anthemis
TypeEmerging player
Description

Fintech-focused VC with deep insurance industry expertise, partnered with multiple insurance carriers. Comparable to AV8's insurtech focus and Allianz partnership, though more narrowly sector-focused.

TypeDirect peer
Description

Early-stage enterprise software investor with an operator-heavy team. Directly comparable to AV8's enterprise focus, similar stage, and similar operator-led investment thesis.

TypeDirect peer
Description

LA-based early-stage VC investing Seed/Series A across enterprise, consumer, and fintech. Comparable to AV8 in stage and multi-sector approach, with similar check sizes.

TypeBroad incumbent
Description

Strategic CVC arm of Sanofi focused on healthcare/biotech. Ruchita Sinha led digital health investing here before joining AV8, providing direct competitive overlap for healthcare deal flow.

10GE Ventures
TypeBroad incumbent
Description

Strategic venture arm of GE that invests across enterprise, healthcare, and industrial tech. Comparable to AV8's Allianz-backed strategic investor profile, and a former employer of AV8's healthcare lead.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment70 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AV8 Ventures

Venture Capitalav8.vc

AV8 Ventures is an early-stage venture capital firm based in Palo Alto that invests Seed and Series A capital in healthcare, enterprise, financial services, and deep tech startups. The firm manages a $180 million fund backed by Allianz.

What AV8 Ventures does

AV8 Ventures is an early-stage venture capital firm headquartered in Palo Alto, California, that invests Seed and Series A capital into startups across four core sectors: healthcare, enterprise software, financial technology and services, and deep tech. Founded in 2018, the firm positions itself as a "full lifecycle investor" that commits early and partners with founders for the long term, providing capital alongside operational expertise and network access. Its portfolio spans approximately 16 named companies, including women's telehealth provider Alpha Medical, cancer-detection startup Delfi Diagnostics, device security firm Eclypsium, mobile observability tool Embrace.io, biotech platform Think Bioscience, healthcare workforce intelligence platform Axuall, Medicare Advantage carrier Clever Care Health Plan, community health value-based-care operator Yuvo Health, microfluidic immunotherapy platform Shennon Bio, AI-based security automation tool Cerby, manufactured-home insurer Covertree, digital SMB insurance agency Glow, cyber insurance carrier Measured Analytics and Insurance, data intelligence platform DataGalaxy, workplace safety wearable Soter Analytics, and financial crime risk scoring firm Elucidate.

The firm's core offering is direct minority equity investment rather than a software product or technology platform. Its differentiation rests on a small core investment team — Managing Director and founder George Ugras, healthcare-focused partner Ruchita Sinha, partner Brett Battles, operating partner Serpil Kuyucak Schiebel, and venture partner Shawn Kung — supplemented by an external bench of approximately ten venture advisors drawn from companies including Asana, Google, UiPath, Square, LinkedIn, Fifth Third Bank, Zest AI, Stanford, and Nvidia. AV8 markets itself through a content-driven approach, publishing sector white papers on enterprise automation, healthcare innovation, and mobility/autonomy, alongside a blog featuring founder interviews and insurtech commentary.

AV8 Ventures generates revenue through the conventional venture capital model of management fees and carried interest on its fund vehicles. Fund II, a $180 million vehicle, was launched in September 2021 with capital commitment from Allianz, one of the world's largest integrated financial services providers. The Allianz relationship functions simultaneously as an anchor LP, a source of patient capital, and a strategic differentiator that grants AV8 proximity to insurance industry expertise and distribution. The firm is privately held, has no public revenue disclosures, and operates from a single Palo Alto office with a core team of five members.

AV8 Ventures firmographics

Firmographics
Name
AV8 Ventures
Legal name
AV8 Ventures
Website
https://av8.vc
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
AV8 Ventures is an early-stage venture capital firm based in Palo Alto that invests Seed and Series A capital in healthcare, enterprise, financial services, and deep tech startups. The firm manages a $180 million fund backed by Allianz.
Ownership category
akta.pro rank

AV8 Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAI
Micro-VC & Angel Funds

Keywords

  • Venture capital investing
  • Early stage funding
  • Seed stage investments
  • Healthcare venture capital
  • Enterprise software investing

Where AV8 Ventures is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AV8 Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Fund Management: VC fund management generating returns through carried interest and management fees from Fund II, a $180M fund backed by Allianz.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

AV8 Ventures product offering

Product offering

Core offering

AV8 Ventures is an early-stage venture capital firm that deploys Seed and Series A capital into startups operating in healthcare, enterprise software, financial technology and services, and deep tech. The firm backs founders with equity capital, operational guidance, and access to a venture advisor network, committing early and partnering for the long term. Its capital is sourced primarily through managed funds (including AV8 Fund II, a $180 million vehicle backed by Allianz).

Product overview

AV8 Ventures is a venture capital firm structured as a single unified investment platform. The firm backs early-stage start-ups focused on four key sectors: Healthcare, Enterprise, Financial Services, and Deep Tech. They typically invest at the Seed or Series A stage and commit early, partnering for the long term. The firm is backed by Allianz and manages multiple funds (including AV8 Fund II, a $180M fund). The investment offering includes capital deployment, operational expertise, network access, and venture advisor support to help founders build their companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • AV8 Ventures Investment Services Early-stage venture capital investment services providing Seed and Series A equity financing to founders building category-defining companies in healthcare, enterprise software, financial technology and services, and deep tech, with operational support and venture advisor network access.

Quantifiable outcome

  • Backed by Allianz, one of the leading integrated financial services providers worldwide

Companies that use AV8 Ventures

Customer profile

Named customers16 records

Segments1 record

Ideal customer profiles1 record

AV8 Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AV8 Ventures partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

AV8 Ventures competitors and assessment

Company assessment

Direct peers

  • Costanoa Ventures: Early-stage venture firm focused on enterprise software and fintech, with offices in Palo Alto. Directly comparable to AV8 for deal flow in B2B software and similar Seed/Series A stage investing approach.
  • Cowboy Ventures: Palo Alto-based early-stage VC investing Seed/Series A across consumer, enterprise, and healthcare. Comparable stage, geography, and operator-friendly model to AV8's investment approach.
  • Lerer Hippeau: Early-stage venture firm investing Seed/Series A in enterprise, consumer, and healthcare. Directly comparable investment stage and thematic breadth to AV8's portfolio construction.
  • M13: Early-stage VC investing across consumer, enterprise, fintech, and healthcare with an operator-driven platform model. Comparable to AV8 in stage, sector focus, and emphasis on operational support.
  • Eniac Ventures: Seed-stage venture firm with focus on enterprise, mobile, and healthcare. Directly comparable to AV8 for early-stage deal flow and similar check sizes at the Seed stage.
  • Wing Venture Capital: Early-stage enterprise software investor with an operator-heavy team. Directly comparable to AV8's enterprise focus, similar stage, and similar operator-led investment thesis.
  • Crosscut Ventures: LA-based early-stage VC investing Seed/Series A across enterprise, consumer, and fintech. Comparable to AV8 in stage and multi-sector approach, with similar check sizes.

Emerging players

  • Anthemis: Fintech-focused VC with deep insurance industry expertise, partnered with multiple insurance carriers. Comparable to AV8's insurtech focus and Allianz partnership, though more narrowly sector-focused.

Broad incumbents

  • Sanofi Ventures: Strategic CVC arm of Sanofi focused on healthcare/biotech. Ruchita Sinha led digital health investing here before joining AV8, providing direct competitive overlap for healthcare deal flow.
  • GE Ventures: Strategic venture arm of GE that invests across enterprise, healthcare, and industrial tech. Comparable to AV8's Allianz-backed strategic investor profile, and a former employer of AV8's healthcare lead.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

AV8 Ventures social profiles

Digital presence

AV8 Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AV8 Ventures leadership team

Management profile

Number of profiles

Profiles5 records

AV8 Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AV8 Ventures M&A and investment

M&A and investment

M&A

Investments70 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AV8 Ventures

What does AV8 Ventures do?

AV8 Ventures is an early-stage venture capital firm that deploys Seed and Series A capital into startups operating in healthcare, enterprise software, financial technology and services, and deep tech. The firm backs founders with equity capital, operational guidance, and access to a venture advisor network, committing early and partnering for the long term. Its capital is sourced primarily through managed funds (including AV8 Fund II, a $180 million vehicle backed by Allianz).

Is AV8 Ventures a public or private company?

AV8 Ventures is a private company. It is classified as corporate owned and is currently operating.

When was AV8 Ventures founded?

AV8 Ventures was founded in 2021. It employs 1 to 10 people.

Where is AV8 Ventures based?

AV8 Ventures is headquartered in Palo Alto, United States, in the North America region.

How does AV8 Ventures make money?

One revenue line is on record: fund Management.

Who are AV8 Ventures's main competitors?

Direct peers on record are Costanoa Ventures, Cowboy Ventures, Lerer Hippeau, M13, Eniac Ventures, Wing Venture Capital and Crosscut Ventures. Anthemis is listed as an emerging player. Broad incumbents are Sanofi Ventures and GE Ventures.

Does AV8 Ventures have an API?

No public API is recorded for AV8 Ventures.

What industry is AV8 Ventures in?

AV8 Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAI, Micro-VC & Angel Funds. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing from multiple investors, bringing its total to $25M. The company appointed Cyril Konto as CEO, with founder Li Sun transitioning to President and CTO. The funds will advance three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma toward clinical development.Pulse 2.0Shennon Biotechnologies Raises $12 Million, Names Cyril Konto As CEO, And Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12 million in financing and appointed Cyril Konto as CEO, bringing total capital to $25 million. The funds will advance three T-cell engager programs for small-cell lung cancer, ovarian cancer, and hepatocellular carcinoma. The company plans to advance a development candidate toward an IND filing within two years.BioSpaceShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing and appointed Cyril Konto as CEO, with founder Li Sun moving to President and CTO. The company has raised $25M to date and is advancing three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma. It plans to advance a development candidate toward IND filing within two years.FinSMEsShennon Biotechnologies Raises $12M in FundingShennon Biotechnologies raised $12M in funding, bringing its total to $25M. The San Francisco-based biotech will use the funds to develop its integrated technology platform and advance its oncology pipeline, which includes three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma.Business Wire BlogShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing and appointed Cyril Konto as CEO, with founder Li Sun moving to president and CTO. The company has raised $25M to date and is advancing three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma. It plans to advance a development candidate toward IND filing and Phase 1 within two years.YuvohealthYuvoYuvo Health closed a $7.3 million seed round led by AlleyCorp, with participation from AV8 Ventures, New York Ventures, and others. The funding will expand its downstate New York program, develop proprietary tools, and strengthen partnerships with Federally Qualified Health Centers. The company plans to expand across New York, the Midwest, and the Mid-Atlantic.Insurance CIO OutlookStartups are Reshaping IT Security in the Insurance IndustryGeorge Ugras, Managing Director at AV8 Ventures, discusses how technology startups are helping transform IT security in the insurance industry, interviewing CEOs including Bel Lepe of Cerby. Cerby, founded in 2020, addresses the challenge of disconnected applications lacking SSO support by using AI agents to automate security tasks like 2FA enrollment and user access management, reporting that 68 percent of security incidents stem from human error. The company partners with a large U.S. insurance company to secure their marketing stack and has achieved 100 percent coverage across customer environments through its automation platform.WebcapitalriesgoOlé Life cierra una ronda de $13M liderada por PayPal Ventures. Participan Mundi Ventures, AV8 y Advent MorroOlé Life closed a $13 million Series B round led by PayPal Ventures, with participation from Mundi Ventures, AV8, and Advent Morro. The funding will support expansion in key Latin American markets and new product offerings. The company reports over $2 billion in total insured value and a network of more than 4,000 distributor partners.HR Tech FeedPeople Analytics Software Raises $41 MillionPeople analytics firm One Model announced a $41 million growth round led by Riverwood Capital, with Queensland Investment Corporation, Geekdom and AV8 Ventures participating. The company said the capital will fund its People Data Cloud and One AI platforms, and it serves nearly a hundred global employers including Colgate-Palmolive. No valuation was disclosed.BusinessCloudInsurTech ‘helps people with chronic illnesses’Bluezone, an InsurTech for chronic illnesses, raised £1.5 million in seed funding led by Insurtech Gateway and AV8 Ventures. It plans to launch a type 2 diabetes product using AI and machine learning to tailor premiums. The company says traditional underwriting is outdated for people with chronic conditions.